Unveiling the Mystery of SUMO-activating enzyme subunit 1: A Groundbreaking Biomarker in the Early Detection and Advancement of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. The discovery and research of effective biomarkers have become prevailing trends. SUMO-activating enzyme subunit 1 (sae1), an E1-activating enzyme, is indispensable for protein SUMOylation. In this study,...

Full description

Saved in:
Bibliographic Details
Published inTransplantation proceedings Vol. 55; no. 4; pp. 945 - 951
Main Authors Wang, Haojun, Yang, Tongwang, Wu, Jiyue, Chen, Dongshan, Wang, Wei
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.05.2023
Subjects
Biomarkers, Tumor
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - genetics
Early Detection of Cancer
Humans
Liver Neoplasms - diagnosis
Prognosis
Signal Transduction
Online AccessGet full text

Cover

More Information
Summary:Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. The discovery and research of effective biomarkers have become prevailing trends. SUMO-activating enzyme subunit 1 (sae1), an E1-activating enzyme, is indispensable for protein SUMOylation. In this study, we conducted a comprehensive analysis of database contents and found that sae1 is highly expressed in HCC and is correlated with poor prognosis. We also identified its regulated transcription factor, rad51, and related signaling pathways. We conclude that sae1 is a promising cancer metabolic biomarker with diagnostic and prognostic value in HCC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0041-1345
1873-2623
DOI:10.1016/j.transproceed.2023.03.042